CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AZN

AZD9833

Phase 3
AstraZeneca PLC (AZN)

Phase 3

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History
Aug '26
AZNPhase 3
Negative

AZD9833 Phase 3 Est. Readout

AZD9833
Aug 2026~
CT.gov
Competitive Landscape

0 competitors in ER-Positive HER2-Negative Breast Cancer

View Full Landscape
Drug Information

Target Indication

ER-Positive HER2-Negative Breast Cancer

Clinical Trial

NCT04711252

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.